Mohammed S Bukari, MD
Hematology/Oncology · Clovis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · Community Health Partners · 497 clinicians in this group
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bukari’s office at (559) 387-1900 to ask if they take your plan before you enroll.
California Medical Board record
Licence A150043 · Current
Licensed to practise in California · since 2017 · expires 2028-08-31 · University of Ghana Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$157,061
Medicare paid this office $157,061 for 589 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 307 | $89,324 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $22,003 | $93 |
| Short return visit (20+ min) | 126 | $10,605 | $67 |
| New patient visit (45+ min) | 75 | $9,537 | $127 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 66 | $6,482 | $95 |
See all 12 services
| Return visit (30+ min) | 307 | $89,324 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $22,003 | $93 |
| Short return visit (20+ min) | 126 | $10,605 | $67 |
| New patient visit (45+ min) | 75 | $9,537 | $127 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 66 | $6,482 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $5,573 | $133 |
| Long return visit (40+ min) | 28 | $4,909 | $140 |
| New patient visit (60+ min) | 13 | $2,311 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,201 | $63 |
| New patient visit (30+ min) | 17 | $1,471 | $87 |
| Injection of drug or substance under skin or into muscle | 26 | $1,137 | $11 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 27 | $97 | None |
Who their Medicare patients are
589 Original Medicare patients in 2024. Average age 71 · Under 65 18% · 85 and older 9% · Women 53% · Also on Medicaid 45% · Health risk score 2.30. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 49% · Chronic kidney disease 45% · Coronary heart disease 35% · Heart failure 33% · Depression 26% · Atrial fibrillation 23% · COPD 19% · Cancer 17% · Stroke 12% · Dementia 8%.
The office billed $567,992, Medicare allowed $209,000 and paid $157,061; for 1,830 services of 21 kinds; $97 of it was for drugs given in the office and $156,964 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 589 | 1,830 | 71 | 2.30 | $567,992 | $157,061 |
| 2023 | 421 | 1,162 | 71 | 2.24 | $345,558 | $103,636 |
| 2022 | 310 | 785 | 69 | 2.04 | $224,411 | $71,877 |
| 2021 | 335 | 821 | 69 | 2.52 | $230,798 | $81,245 |
| 2020 | 483 | 1,210 | 69 | 2.59 | $322,774 | $98,264 |
| 2019 | 436 | 1,310 | 70 | 2.40 | $365,326 | $120,375 |
| 2018 | 304 | 747 | 71 | 2.36 | $232,993 | $72,163 |
| 2017 | 243 | 288 | 66 | 2.98 | $153,591 | $27,451 |
| 2016 | 227 | 247 | 66 | 3.36 | $131,540 | $19,633 |
| 2015 | 103 | 114 | 65 | 2.94 | $56,026 | $8,844 |
| 2014 | 267 | 861 | 70 | 2.46 | $101,890 | $71,143 |
| 2013 | 524 | 1,702 | 71 | 2.22 | $189,496 | $140,506 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 231 | $60,068 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $10,334 | $95 |
| New patient visit (45+ min) | 64 | $7,823 | $122 |
| Short return visit (20+ min) | 76 | $5,093 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,068 | $103 |
| Long return visit (40+ min) | 24 | $3,867 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,593 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,179 | $138 |
| New patient visit (60+ min) | 18 | $2,516 | $140 |
| Injection of drug or substance under skin or into muscle | 26 | $477 | $11 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $46 | None |
2022: 10 services
| Return visit (30+ min) | 146 | $35,290 | $94 |
| Long return visit (40+ min) | 32 | $7,032 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $6,060 | $82 |
| New patient visit (45+ min) | 41 | $4,864 | $119 |
| Short return visit (20+ min) | 66 | $4,702 | $60 |
| New patient visit (60+ min) | 24 | $3,839 | $160 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 45 | $3,467 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,884 | $160 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,850 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,154 | $52 |
2021: 10 services
| Return visit (30+ min) | 131 | $34,194 | $105 |
| Long return visit (40+ min) | 40 | $9,973 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $9,235 | $85 |
| Short return visit (20+ min) | 63 | $5,039 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,480 | $112 |
| New patient visit (45+ min) | 31 | $4,163 | $134 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 48 | $4,143 | $83 |
| New patient visit (60+ min) | 16 | $2,987 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,705 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,196 | $59 |
2020: 11 services
| Return visit (30+ min) | 340 | $62,477 | $85 |
| Long return visit (40+ min) | 48 | $9,686 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $4,777 | $85 |
| Short return visit (20+ min) | 57 | $3,967 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $3,898 | $108 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 41 | $3,069 | $75 |
| New patient visit (45+ min) | 19 | $2,526 | $133 |
| New patient visit (60+ min) | 15 | $2,075 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $1,889 | $59 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 43 | $568 | $12 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $37 | None |
2019: 10 services
| Return visit (30+ min) | 285 | $40,512 | $84 |
| Long return visit (40+ min) | 98 | $29,121 | $108 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 18 | $17,875 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $8,299 | $84 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 73 | $6,010 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,812 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,524 | $110 |
| New patient visit (60+ min) | 23 | $3,517 | $153 |
| New patient visit (45+ min) | 27 | $3,200 | $119 |
| Short return visit (20+ min) | 30 | $1,955 | $59 |
2018: 11 services
| Return visit (30+ min) | 109 | $13,302 | $88 |
| Long return visit (40+ min) | 66 | $10,717 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $7,676 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,287 | $107 |
| Long return visit (40+ min) | 34 | $5,707 | $119 |
| New patient visit (60+ min) | 34 | $4,412 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,042 | $160 |
| Return visit (30+ min) | 37 | $3,007 | $63 |
| New patient visit (60+ min) | 17 | $2,574 | $151 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 29 | $2,358 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,237 | $59 |
2017: 8 services
| Initial hospital observation care per day, typically 50 minutes | 85 | $8,617 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,024 | $159 |
| Hospital observation care on day of discharge | 51 | $2,892 | $56 |
| Initial hospital observation care per day, typically 70 minutes | 20 | $2,838 | $142 |
| New patient visit (60+ min) | 18 | $2,198 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,608 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,433 | $110 |
| Follow-up observation care per day, typically 25 minutes | 22 | $1,224 | $56 |
2016: 5 services
| Initial hospital observation care per day, typically 30 minutes | 104 | $8,164 | $78 |
| Hospital observation care on day of discharge | 62 | $3,540 | $57 |
| Initial hospital observation care per day, typically 50 minutes | 33 | $3,516 | $107 |
| Initial hospital observation care per day, typically 70 minutes | 12 | $1,748 | $146 |
| Follow-up observation care per day, typically 25 minutes | 19 | $1,085 | $57 |
2015: 2 services
| Initial hospital observation care per day, typically 30 minutes | 61 | $4,942 | $81 |
| Hospital observation care on day of discharge | 32 | $1,869 | $58 |
2014: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 163 | $37,084 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $14,082 | $142 |
| Hospital discharge day management, more than 30 minutes | 102 | $8,448 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $7,667 | $54 |
| Hospital observation care on day of discharge | 11 | $612 | $56 |
2013: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 334 | $69,422 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 179 | $27,696 | $146 |
| Hospital discharge day management, more than 30 minutes | 213 | $18,760 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 110 | $15,963 | $54 |
| Initial hospital observation care per day, typically 70 minutes | 20 | $2,588 | $129 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,611 | $95 |
| Hospital observation care on day of discharge | 28 | $1,484 | $53 |
| Follow-up observation care per day, typically 35 minutes | 11 | $1,070 | $76 |
Medicaid work
$38,428 in 2024
Medicaid paid $38,428 for 3,310 billed services this clinician did in 2024, up to 87 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 925 | $16,994 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 487 | $9,197 |
| COMPREHENSIVE METABOLIC PANEL | 386 | $3,726 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 397 | $2,823 |
| Lactate dehydrogenase (LD), (LDH) | 306 | $1,305 |
| BLOOD COUNT RETICULOCYTE AUTOMATED | 250 | $815 |
| New patient visit (45+ min) | 57 | $729 |
| Uric acid; blood | 276 | $712 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 33 | $465 |
| Short return visit (20+ min) | 37 | $325 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 14 | $265 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 21 | $260 |
| 2024 | 3,310 | 18 | 87 | $38,428 |
| 2023 | 2,861 | 17 | 103 | $18,205 |
| 2022 | 3,196 | 18 | 76 | $18,982 |
| 2021 | 1,797 | 8 | 30 | $12,463 |
| 2020 | 753 | 4 | 35 | $14,965 |
| 2019 | 473 | 5 | 29 | $17,988 |
| 2018 | 810 | 6 | 61 | $14,483 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 1,009 | $8,400 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 239 | $2,871 |
| COMPREHENSIVE METABOLIC PANEL | 364 | $1,950 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 382 | $1,450 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 92 | $1,014 |
| Lactate dehydrogenase (LD), (LDH) | 213 | $450 |
| BLOOD COUNT RETICULOCYTE AUTOMATED | 225 | $439 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 32 | $351 |
| New patient visit (45+ min) | 14 | $283 |
| Uric acid; blood | 196 | $260 |
| Long return visit (40+ min) | 12 | $212 |
| IP/OBS CONSLTJ NEW/EST PT HIGH MDM 80 MINUTES | 15 | $192 |
2022
| Return visit (30+ min) | 685 | $7,810 |
| COMPREHENSIVE METABOLIC PANEL | 546 | $3,721 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 532 | $2,453 |
| BLOOD COUNT RETICULOCYTE AUTOMATED | 297 | $861 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 71 | $842 |
| Lactate dehydrogenase (LD), (LDH) | 311 | $665 |
| Long return visit (40+ min) | 32 | $656 |
| Uric acid; blood | 301 | $562 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 28 | $379 |
| Measurement of magnesium | 54 | $318 |
| Infusion, normal saline solution, 250 cc | 131 | $176 |
| Short return visit (20+ min) | 37 | $152 |
2021
| COMPREHENSIVE METABOLIC PANEL | 459 | $4,740 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 463 | $3,372 |
| Return visit (30+ min) | 213 | $1,847 |
| Lactate dehydrogenase (LD), (LDH) | 235 | $902 |
| BLOOD COUNT RETICULOCYTE AUTOMATED | 174 | $630 |
| Uric acid; blood | 209 | $530 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $250 |
| Short return visit (20+ min) | 14 | $192 |
2020
| Return visit (30+ min) | 474 | $11,943 |
| COMPREHENSIVE METABOLIC PANEL | 117 | $1,537 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 146 | $1,411 |
| Lactate dehydrogenase (LD), (LDH) | 16 | $74 |
2019
| Return visit (30+ min) | 199 | $7,858 |
| Long return visit (40+ min) | 158 | $7,828 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 57 | $1,687 |
| COMPREHENSIVE METABOLIC PANEL | 30 | $359 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 29 | $256 |
2018
| Long return visit (40+ min) | 304 | $5,823 |
| Return visit (30+ min) | 267 | $3,879 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 127 | $2,966 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 70 | $1,138 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 25 | $541 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 17 | $138 |
Drugs they prescribed that Part D paid
$6,008,508
Pharmacies billed $6,008,508 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (111 of 2,781) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 18% of their opioid prescriptions.
2,109 generic and 672 brand-name prescriptions · $6,008,508 in drug cost · 137 antibiotic prescriptions to 45 people · 29 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 94 | $1,253,923 | $13,340 |
| Promacta | 46 | $500,238 | $10,875 |
| Revlimid | 28 | $485,158 | $17,327 |
| Jakafi | 26 | $462,961 | $17,806 |
| Iclusig | 21 | $441,151 | $21,007 |
See all 54 drugs
| Lenalidomide | 94 | $1,253,923 | $13,340 |
| Promacta | 46 | $500,238 | $10,875 |
| Revlimid | 28 | $485,158 | $17,327 |
| Jakafi | 26 | $462,961 | $17,806 |
| Iclusig | 21 | $441,151 | $21,007 |
| Imbruvica | 13 | $213,698 | $16,438 |
| Sprycel | 28 | $206,785 | $7,385 |
| Eliquis | 249 | $198,091 | $796 |
| Doptelet | 11 | $194,745 | $17,704 |
| Lonsurf | 14 | $98,002 | $7,000 |
| Venclexta | 28 | $58,886 | $2,103 |
| Xarelto | 38 | $42,885 | $1,129 |
| Atovaquone | 36 | $11,841 | $329 |
| Enoxaparin | 14 | $5,675 | $405 |
| Sucralfate | 14 | $3,734 | $267 |
| Sirolimus | 12 | $3,368 | $281 |
| Acyclovir | 203 | $2,725 | $13 |
| Fluconazole | 51 | $2,257 | $44 |
| Anagrelide | 22 | $2,112 | $96 |
| Potassium Chloride | 105 | $1,989 | $19 |
| Hydroxyurea | 99 | $1,443 | $15 |
| Valacyclovir | 36 | $1,199 | $33 |
| Gabapentin | 116 | $1,159 | $10 |
| Pantoprazole | 113 | $1,101 | $10 |
| Dexamethasone | 41 | $1,041 | $25 |
| Allopurinol | 174 | $944 | $5 |
| Hydrocodone-Acetaminophen | 60 | $923 | $15 |
| Olanzapine | 43 | $708 | $16 |
| Lidocaine | 12 | $686 | $57 |
| Morphine Sulfate Er | 15 | $497 | $33 |
| Methenamine Hippurate | 12 | $455 | $38 |
| Omeprazole | 15 | $296 | $20 |
| Ondansetron Odt | 42 | $283 | $7 |
| Tamsulosin | 33 | $280 | $8 |
| Famotidine | 29 | $278 | $10 |
| Prochlorperazine Maleate | 43 | $262 | $6 |
| Sulfamethoxazole-Trimethoprim | 69 | $252 | $4 |
| Levofloxacin | 33 | $252 | $8 |
| Levothyroxine | 38 | $236 | $6 |
| Loperamide | 12 | $222 | $18 |
| Fluticasone Propionate | 25 | $207 | $8 |
| Prednisone | 40 | $205 | $5 |
| Lidocaine-Prilocaine | 14 | $199 | $14 |
| Oxycodone | 19 | $195 | $10 |
| Ondansetron | 40 | $189 | $5 |
| Furosemide | 48 | $172 | $4 |
| Montelukast | 27 | $126 | $5 |
| Klor-Con 10 | 11 | $118 | $11 |
| Losartan | 13 | $87 | $7 |
| Folic Acid | 19 | $73 | $4 |
| Amoxicillin-Clavulanate Potass | 11 | $73 | $7 |
| Metoprolol | 17 | $67 | $4 |
| Doxycycline Monohydrate | 11 | $66 | $6 |
| Amlodipine Besylate | 27 | $62 | $2 |
Year by year
| 2024 | 2,781 | 252 | 4% (111) | 24% | $6,008,508 |
| 2023 | 2,266 | 216 | 6% (142) | None | $4,280,602 |
| 2022 | 2,033 | 183 | 5% (95) | None | $3,495,749 |
| 2021 | 1,412 | 122 | 6% (90) | None | $1,952,349 |
| 2020 | 1,241 | 111 | 5% (64) | None | $1,401,534 |
| 2019 | 850 | 105 | None | 20% | $857,625 |
| 2018 | 596 | 72 | 4% (22) | 19% | $748,645 |
| 2017 | 232 | 84 | 13% (30) | None | $48,137 |
| 2016 | 367 | 104 | 17% (62) | None | $11,915 |
| 2015 | 221 | 88 | 18% (39) | None | $6,934 |
| 2014 | 413 | 102 | 8% (34) | None | $16,792 |
| 2013 | 749 | 162 | 5% (38) | None | $42,488 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Lenalidomide | 49 | $719,041 | $14,674 |
| Iclusig | 28 | $593,624 | $21,201 |
| Pomalyst | 21 | $512,679 | $24,413 |
| Revlimid | 21 | $397,239 | $18,916 |
| Promacta | 27 | $333,346 | $12,346 |
| Venclexta | 48 | $262,420 | $5,467 |
| Jakafi | 13 | $258,975 | $19,921 |
| Sprycel | 18 | $180,339 | $10,019 |
| Eliquis | 150 | $127,083 | $847 |
| Xarelto | 43 | $46,781 | $1,088 |
| Pegasys | 11 | $45,985 | $4,180 |
| Zarxio | 12 | $38,211 | $3,184 |
| Posaconazole | 12 | $18,320 | $1,527 |
| Atovaquone | 15 | $9,859 | $657 |
| Savaysa | 12 | $5,197 | $433 |
| Acyclovir | 172 | $3,549 | $21 |
| Hydroxyurea | 89 | $2,835 | $32 |
| Fluconazole | 39 | $2,474 | $63 |
| Pantoprazole | 124 | $1,499 | $12 |
| Potassium Chloride | 81 | $1,319 | $16 |
| Gabapentin | 108 | $1,295 | $12 |
| Allopurinol | 100 | $1,255 | $13 |
| Valacyclovir | 17 | $1,243 | $73 |
| Hydrocodone-Acetaminophen | 65 | $915 | $14 |
| Dexamethasone | 47 | $844 | $18 |
| Levofloxacin | 70 | $687 | $10 |
| Prochlorperazine Maleate | 41 | $452 | $11 |
| Oxycodone-Acetaminophen | 15 | $411 | $27 |
| Ursodiol | 14 | $405 | $29 |
| Morphine Sulfate Er | 19 | $390 | $21 |
| Sulfamethoxazole-Trimethoprim | 59 | $300 | $5 |
| Amlodipine Besylate | 19 | $292 | $15 |
| Oxycodone | 20 | $287 | $14 |
| Montelukast | 29 | $285 | $10 |
| Famotidine | 20 | $274 | $14 |
| Ondansetron Odt | 20 | $270 | $13 |
| Atorvastatin | 20 | $263 | $13 |
| Furosemide | 49 | $262 | $5 |
| Levothyroxine | 14 | $239 | $17 |
| Amoxicillin-Clavulanate Potass | 25 | $238 | $10 |
| Fluticasone Propionate | 14 | $217 | $16 |
| Duloxetine | 13 | $195 | $15 |
| Ondansetron | 34 | $184 | $5 |
| Lidocaine-Prilocaine | 11 | $169 | $15 |
| Cyclobenzaprine | 13 | $165 | $13 |
| Tamsulosin | 20 | $156 | $8 |
| Constulose | 14 | $138 | $10 |
| Prednisone | 28 | $126 | $5 |
| Losartan | 16 | $121 | $8 |
| Folic Acid | 18 | $28 | $2 |
2022: 49 drugs
| Revlimid | 48 | $896,676 | $18,681 |
| Iclusig | 23 | $495,036 | $21,523 |
| Pomalyst | 20 | $428,803 | $21,440 |
| Jakafi | 17 | $296,529 | $17,443 |
| Inrebic | 11 | $252,089 | $22,917 |
| Sprycel | 16 | $149,162 | $9,323 |
| Venclexta | 32 | $100,544 | $3,142 |
| Pegasys | 22 | $94,146 | $4,279 |
| Eliquis | 109 | $79,381 | $728 |
| Xarelto | 37 | $35,949 | $972 |
| Endari | 12 | $30,267 | $2,522 |
| Atovaquone | 21 | $8,039 | $383 |
| Savaysa | 12 | $5,046 | $420 |
| Fluconazole | 30 | $2,776 | $93 |
| Sucralfate | 18 | $2,682 | $149 |
| Acyclovir | 156 | $2,340 | $15 |
| Hydroxyurea | 72 | $2,205 | $31 |
| Potassium Chloride | 67 | $1,470 | $22 |
| Gabapentin | 109 | $1,377 | $13 |
| Pantoprazole | 124 | $1,224 | $10 |
| Synthroid | 11 | $890 | $81 |
| Hydrocodone-Acetaminophen | 51 | $854 | $17 |
| Allopurinol | 91 | $769 | $8 |
| Dexamethasone | 58 | $717 | $12 |
| Valacyclovir | 13 | $695 | $53 |
| Levetiracetam | 11 | $607 | $55 |
| Fluticasone Propionate | 30 | $606 | $20 |
| Levofloxacin | 49 | $410 | $8 |
| Ondansetron Odt | 21 | $407 | $19 |
| Montelukast | 25 | $404 | $16 |
| Prochlorperazine Maleate | 31 | $367 | $12 |
| Loperamide | 19 | $344 | $18 |
| Famotidine | 25 | $304 | $12 |
| Oxycodone | 15 | $300 | $20 |
| Prednisone | 43 | $295 | $7 |
| Ondansetron | 34 | $285 | $8 |
| Duloxetine | 16 | $252 | $16 |
| Warfarin | 31 | $244 | $8 |
| Sulfamethoxazole-Trimethoprim | 58 | $208 | $4 |
| Furosemide | 55 | $195 | $4 |
| Morphine Sulfate Er | 11 | $182 | $17 |
| Levothyroxine | 13 | $166 | $13 |
| Amlodipine Besylate | 14 | $157 | $11 |
| Atorvastatin | 11 | $137 | $12 |
| Amoxicillin-Clavulanate Potass | 12 | $130 | $11 |
| Tamsulosin | 26 | $85 | $3 |
| Metformin | 12 | $55 | $5 |
| Folic Acid | 19 | $52 | $3 |
| Lorazepam | 14 | $49 | $3 |
2021: 39 drugs
| Revlimid | 28 | $494,695 | $17,668 |
| Pomalyst | 11 | $234,007 | $21,273 |
| Sprycel | 16 | $138,942 | $8,684 |
| Venclexta | 13 | $107,146 | $8,242 |
| Pegasys | 16 | $64,390 | $4,024 |
| Eliquis | 69 | $42,859 | $621 |
| Endari | 13 | $31,453 | $2,419 |
| Xarelto | 26 | $24,185 | $930 |
| Oxycontin | 12 | $8,816 | $735 |
| Savaysa | 12 | $4,934 | $411 |
| Hydroxyurea | 81 | $2,296 | $28 |
| Potassium Chloride | 36 | $1,489 | $41 |
| Acyclovir | 104 | $1,409 | $14 |
| Dexamethasone | 39 | $1,033 | $26 |
| Gabapentin | 82 | $944 | $12 |
| Duloxetine | 29 | $847 | $29 |
| Pantoprazole | 83 | $749 | $9 |
| Ondansetron Odt | 18 | $743 | $41 |
| Fluconazole | 12 | $555 | $46 |
| Hydrocodone-Acetaminophen | 37 | $543 | $15 |
| Levofloxacin | 15 | $529 | $35 |
| Ondansetron | 35 | $493 | $14 |
| Hydromorphone | 15 | $474 | $32 |
| Prochlorperazine Maleate | 35 | $411 | $12 |
| Montelukast | 26 | $384 | $15 |
| Diclofenac | 12 | $276 | $23 |
| Warfarin | 14 | $250 | $18 |
| Sulfamethoxazole-Trimethoprim | 51 | $248 | $5 |
| Fluticasone Propionate | 18 | $244 | $14 |
| Levetiracetam | 15 | $228 | $15 |
| Levothyroxine | 15 | $215 | $14 |
| Allopurinol | 18 | $204 | $11 |
| Lactulose | 16 | $194 | $12 |
| Prednisone | 22 | $152 | $7 |
| Furosemide | 32 | $124 | $4 |
| Carisoprodol | 12 | $101 | $8 |
| Famotidine | 13 | $80 | $6 |
| Zolpidem | 13 | $55 | $4 |
| Amlodipine Besylate | 14 | $32 | $2 |
2020: 36 drugs
| Revlimid | 45 | $790,149 | $17,559 |
| Sprycel | 12 | $115,217 | $9,601 |
| Pegasys | 23 | $93,926 | $4,084 |
| Eliquis | 59 | $41,219 | $699 |
| Venclexta | 14 | $33,621 | $2,401 |
| Xarelto | 47 | $32,677 | $695 |
| Pradaxa | 13 | $8,979 | $691 |
| Potassium Chloride | 51 | $6,645 | $130 |
| Savaysa | 12 | $4,823 | $402 |
| Enoxaparin | 13 | $4,789 | $368 |
| Voriconazole | 11 | $3,478 | $316 |
| Midodrine | 19 | $2,457 | $129 |
| Clinimix E | 12 | $2,166 | $180 |
| Hydroxyurea | 45 | $1,569 | $35 |
| Acyclovir | 87 | $1,300 | $15 |
| Valacyclovir | 12 | $1,273 | $106 |
| Levofloxacin | 20 | $1,153 | $58 |
| Dexamethasone | 40 | $1,122 | $28 |
| Gabapentin | 70 | $700 | $10 |
| Pantoprazole | 75 | $699 | $9 |
| Ondansetron | 34 | $491 | $14 |
| Oxycodone | 22 | $468 | $21 |
| Prochlorperazine Maleate | 23 | $310 | $13 |
| Morphine Sulfate Er | 12 | $293 | $24 |
| Mirtazapine | 16 | $266 | $17 |
| Levothyroxine | 16 | $246 | $15 |
| Ondansetron Odt | 17 | $223 | $13 |
| Sulfamethoxazole-Trimethoprim | 37 | $221 | $6 |
| Hydrocodone-Acetaminophen | 18 | $208 | $12 |
| Levetiracetam | 12 | $194 | $16 |
| Lactulose | 19 | $184 | $10 |
| Warfarin | 18 | $166 | $9 |
| Furosemide | 25 | $138 | $6 |
| Amoxicillin-Clavulanate Potass | 14 | $125 | $9 |
| Prednisone | 23 | $122 | $5 |
| Lorazepam | 15 | $77 | $5 |
2019: 24 drugs
| Revlimid | 18 | $272,287 | $15,127 |
| Venclexta | 11 | $69,767 | $6,342 |
| Eliquis | 28 | $17,932 | $640 |
| Xarelto | 19 | $11,089 | $584 |
| Enoxaparin | 17 | $9,684 | $570 |
| Pradaxa | 12 | $7,949 | $662 |
| Potassium Chloride | 42 | $4,947 | $118 |
| Hydroxyurea | 39 | $1,208 | $31 |
| Midodrine | 12 | $983 | $82 |
| Dexamethasone | 44 | $900 | $20 |
| Acyclovir | 70 | $685 | $10 |
| Gabapentin | 51 | $660 | $13 |
| Pantoprazole | 51 | $654 | $13 |
| Ciprofloxacin | 17 | $485 | $29 |
| Levetiracetam | 11 | $272 | $25 |
| Warfarin | 19 | $204 | $11 |
| Prednisone | 29 | $204 | $7 |
| Sulfamethoxazole-Trimethoprim | 36 | $193 | $5 |
| Prochlorperazine Maleate | 20 | $181 | $9 |
| Ondansetron | 20 | $157 | $8 |
| Doxycycline Monohydrate | 12 | $137 | $11 |
| Lorazepam | 15 | $135 | $9 |
| Clopidogrel | 15 | $60 | $4 |
| Lactulose | 23 | $40 | $2 |
2018: 19 drugs
| Revlimid | 33 | $414,806 | $12,570 |
| Xarelto | 16 | $7,046 | $440 |
| Enoxaparin | 12 | $1,992 | $166 |
| Potassium Chloride | 11 | $1,278 | $116 |
| Fluconazole | 15 | $836 | $56 |
| Hydroxyurea | 31 | $831 | $27 |
| Dexamethasone | 34 | $735 | $22 |
| Gabapentin | 27 | $711 | $26 |
| Synthroid | 12 | $503 | $42 |
| Acyclovir | 41 | $419 | $10 |
| Pantoprazole | 36 | $412 | $11 |
| Hydrocodone-Acetaminophen | 17 | $316 | $19 |
| Ondansetron | 37 | $294 | $8 |
| Ciprofloxacin | 15 | $209 | $14 |
| Prochlorperazine Maleate | 30 | $191 | $6 |
| Sulfamethoxazole-Trimethoprim | 23 | $143 | $6 |
| Prednisone | 18 | $77 | $4 |
| Lorazepam | 11 | $68 | $6 |
| Clopidogrel | 11 | $40 | $4 |
2017: 4 drugs
| Pantoprazole | 25 | $360 | $14 |
| Ondansetron | 15 | $119 | $8 |
| Hydrocodone-Acetaminophen | 13 | $92 | $7 |
| Prednisone | 18 | $62 | $3 |
2016: 9 drugs
| Oxycodone | 17 | $817 | $48 |
| Hydrocodone-Acetaminophen | 26 | $556 | $21 |
| Potassium Chloride | 13 | $273 | $21 |
| Sucralfate | 13 | $262 | $20 |
| Doxycycline Hyclate | 15 | $190 | $13 |
| Pantoprazole | 25 | $185 | $7 |
| Ondansetron | 13 | $176 | $14 |
| Amlodipine Besylate | 18 | $86 | $5 |
| Prednisone | 23 | $79 | $3 |
2015: 4 drugs
| Hydrocodone-Acetaminophen | 19 | $277 | $15 |
| Ondansetron | 12 | $156 | $13 |
| Pantoprazole | 14 | $89 | $6 |
| Prednisone | 11 | $44 | $4 |
2014: 11 drugs
| Sucralfate | 16 | $496 | $31 |
| Potassium Chloride | 19 | $257 | $14 |
| Pantoprazole | 20 | $255 | $13 |
| Nitrostat | 16 | $229 | $14 |
| Levofloxacin | 21 | $193 | $9 |
| Atorvastatin | 12 | $174 | $15 |
| Klor-Con M20 | 12 | $154 | $13 |
| Furosemide | 26 | $93 | $4 |
| Prednisone | 18 | $89 | $5 |
| Lisinopril | 14 | $53 | $4 |
| Metoprolol | 11 | $31 | $3 |
2013: 17 drugs
| Isosorbide Dinitrate | 14 | $890 | $64 |
| Proair Hfa | 14 | $657 | $47 |
| Sucralfate | 17 | $600 | $35 |
| Levofloxacin | 44 | $593 | $13 |
| Atorvastatin | 22 | $510 | $23 |
| Pantoprazole | 35 | $407 | $12 |
| Potassium Chloride | 23 | $315 | $14 |
| Hydralazine | 16 | $305 | $19 |
| Amox Tr-Potassium Clavulanate | 18 | $270 | $15 |
| Furosemide | 43 | $182 | $4 |
| Nitrostat | 16 | $178 | $11 |
| Prednisone | 50 | $174 | $3 |
| Lisinopril | 25 | $118 | $5 |
| Amlodipine Besylate | 15 | $115 | $8 |
| Metoprolol | 24 | $107 | $4 |
| Carvedilol | 14 | $91 | $7 |
| Levothyroxine | 12 | $63 | $5 |
Money from drug and device companies
$10,510 in 2025
| 2025 | 30 | 89 | $7,870 | $10,510 |
| 2024 | 19 | 59 | $2,700 | $3,967 |
| 2023 | 20 | 56 | $2,775 | $3,811 |
| 2022 | 13 | 24 | $9,749 | $12,348 |
| 2021 | 4 | 5 | $1,440 | $1,617 |
| 2020 | 9 | 13 | None | $359 |
| 2019 | 26 | 93 | $1,500 | $3,469 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Agios Pharmaceuticals | Pyrukynd | $6,519 | 10 payments
|
| Stemline Therapeutics | Elzonris | $2,191 | 2 payments
|
| Astellas Pharma US | Cresemba | $217 | 7 payments
|
| Daiichi Sankyo | Vanflyta | $177 | 13 payments
|
| Janssen Scientific Affairs | Talvey | $150 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $140 | 11 payments
|
See all 89 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-23 | None | $16 |
| Daiichi Sankyo | Meals · 2025-12-22 | Vanflyta | $21 |
| GlaxoSmithKline | Meals · 2025-12-18 | Blenrep | $1 |
| GlaxoSmithKline | Meals · 2025-12-18 | Blenrep | $12 |
| Array Biopharma | Meals · 2025-12-18 | Lorbrena | $19 |
| PharmaEssentia USA | Meals · 2025-12-17 | Besremi | $23 |
| Nuvation Bio | Meals · 2025-12-16 | Ibtrozi | $24 |
| Incyte | Meals · 2025-12-12 | Monjuvi | $17 |
| Daiichi Sankyo | Meals · 2025-12-10 | Datroway | $29 |
| Genmab U.S. | Meals · 2025-12-04 | Epkinly | $34 |
| Astellas Pharma US | Meals · 2025-12-04 | Cresemba | $25 |
| Abbvie | Meals · 2025-12-02 | Venclexta | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-01 | None | $21 |
| GlaxoSmithKline | Meals · 2025-11-24 | Blenrep | $1 |
| GlaxoSmithKline | Meals · 2025-11-24 | Blenrep | $23 |
| Genzyme | Meals · 2025-11-24 | Sarclisa | $23 |
| Servier Pharmaceuticals | Meals · 2025-11-18 | Tibsovo | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-17 | Imfinzi | $14 |
| Genzyme | Meals · 2025-11-12 | Cablivi | $30 |
| Novartis Pharmaceuticals | Meals · 2025-11-04 | Scemblix | $23 |
| Astellas Pharma US | Meals · 2025-10-27 | Vyloy | $20 |
| Astellas Pharma US | Meals · 2025-10-27 | Vyloy | $12 |
| SpringWorks Therapeutics | Meals · 2025-10-16 | Ogsiveo | $34 |
| Array Biopharma | Meals · 2025-10-09 | Lorbrena | $21 |
| Daiichi Sankyo | Meals · 2025-09-29 | Vanflyta | $10 |
| Astellas Pharma US | Meals · 2025-09-25 | Cresemba | $16 |
| Accord Healthcare | Meals · 2025-09-20 | Camcevi | $21 |
| Agios Pharmaceuticals | Meals · 2025-09-15 | Pyrukynd | $30 |
| Incyte | Meals · 2025-09-11 | Monjuvi | $24 |
| GlaxoSmithKline | Meals · 2025-09-04 | Ojjaara | $14 |
| Emmaus Medical | Meals · 2025-08-28 | Endari | $8 |
| Abbvie | Meals · 2025-08-28 | Venclexta | $16 |
| Iovance Biotherapeutics | Meals · 2025-08-27 | Amtagvi | $23 |
| SpringWorks Therapeutics | Meals · 2025-08-26 | Ogsiveo | $38 |
| Janssen Scientific Affairs | Consulting · 2025-08-15 | Talvey | $150 |
| Celgene | Meals · 2025-07-30 | Opdivo | $22 |
| GlaxoSmithKline | Meals · 2025-07-29 | Ojjaara | $12 |
| Agios Pharmaceuticals | Meals · 2025-07-21 | Pyrukynd | $30 |
| Daiichi Sankyo | Meals · 2025-07-09 | Vanflyta | $15 |
| Eisai | Meals · 2025-07-02 | Lenvima | $29 |
| Array Biopharma | Meals · 2025-06-27 | Xalkori | $20 |
| Caris MPI | Meals · 2025-06-24 | Mi Cancer Seek | $24 |
| Daiichi Sankyo | Meals · 2025-06-19 | Vanflyta | $9 |
| Abbvie | Meals · 2025-06-19 | Imbruvica | $16 |
| Agios Pharmaceuticals | Consulting · 2025-06-18 | Pyrukynd | $5,550 |
| Agios Pharmaceuticals | Travel · 2025-06-18 | Pyrukynd | $52 |
| Daiichi Sankyo | Meals · 2025-06-10 | Vanflyta | $10 |
| GlaxoSmithKline | Meals · 2025-06-06 | Ojjaara | $1 |
| GlaxoSmithKline | Meals · 2025-06-04 | Ojjaara | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-30 | None | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-27 | None | $25 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Scemblix | $22 |
| Stemline Therapeutics | Meals · 2025-05-21 | Elzonris | $21 |
| Abbvie | Meals · 2025-05-19 | Imbruvica | $24 |
| Agios Pharmaceuticals | Meals · 2025-05-17 | Pyrukynd | $55 |
| Agios Pharmaceuticals | Meals · 2025-05-17 | Pyrukynd | $140 |
| Agios Pharmaceuticals | Travel · 2025-05-17 | Pyrukynd | $365 |
| Agios Pharmaceuticals | Travel · 2025-05-17 | Pyrukynd | $227 |
| Agios Pharmaceuticals | Meals · 2025-05-17 | Pyrukynd | $30 |
| Agios Pharmaceuticals | Meals · 2025-05-17 | Pyrukynd | $40 |
| Daiichi Sankyo | Meals · 2025-05-13 | Vanflyta | $9 |
| GlaxoSmithKline | Meals · 2025-05-08 | Ojjaara | $26 |
| Daiichi Sankyo | Meals · 2025-05-08 | Vanflyta | $20 |
| Stemline Therapeutics | Consulting · 2025-05-02 | Elzonris | $2,170 |
| Pfizer | Meals · 2025-05-01 | Padcev | $22 |
| Astellas Pharma US | Meals · 2025-04-30 | Cresemba | $22 |
| Seagen | Education · 2025-04-28 | None | $89 |
| Daiichi Sankyo | Meals · 2025-04-15 | Vanflyta | $9 |
| Novartis Pharmaceuticals | Meals · 2025-04-04 | Scemblix | $17 |
| Daiichi Sankyo | Meals · 2025-04-03 | Vanflyta | $6 |
| Janssen Biotech | Meals · 2025-03-24 | Erleada | $22 |
| Pfizer | Meals · 2025-03-21 | Ibrance | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-07 | None | $16 |
| Astellas Pharma US | Meals · 2025-03-06 | Xtandi | $23 |
| Celgene | Meals · 2025-02-21 | Opdivo | $19 |
| Celgene | Meals · 2025-02-20 | Reblozyl | $16 |
| Daiichi Sankyo | Meals · 2025-02-20 | Vanflyta | $14 |
| Genzyme | Meals · 2025-02-14 | None | $24 |
| Exelixis | Meals · 2025-02-11 | Cabometyx | $22 |
| Daiichi Sankyo | Meals · 2025-02-05 | Vanflyta | $5 |
| Pfizer | Meals · 2025-01-30 | Ibrance | $19 |
| Pfizer | Meals · 2025-01-30 | Ibrance | $3 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Opdualag | $21 |
| Sobi | Education · 2025-01-17 | None | $99 |
| Daiichi Sankyo | Meals · 2025-01-14 | Vanflyta | $21 |
| GlaxoSmithKline | Meals · 2025-01-10 | Ojjaara | $1 |
| GlaxoSmithKline | Meals · 2025-01-09 | Ojjaara | $15 |
| Astellas Pharma US | Education · 2025-01-08 | None | $99 |
| Syndax Pharmaceuticals | Meals · 2025-01-06 | None | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,967
| Novartis Pharmaceuticals | Scemblix | $2,859 | 11 payments
|
| Pfizer | Elrexfio | $257 | 6 payments
|
| Astellas Pharma US | Padcev | $136 | 4 payments
|
| Daiichi Sankyo | Vanflyta | $131 | 9 payments
|
| Celgene | Reblozyl | $87 | 4 payments
|
| Servier Pharmaceuticals | Tibsovo | $86 | 4 payments
|
| Janssen Biotech | Erleada | $86 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $73 | 4 payments
|
| Exelixis | Cabometyx | $34 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $30 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $30 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $28 | 1 payment
|
| Genentech USA | Columvi | $26 | 1 payment
|
| Taiho Oncology | Lonsurf | $26 | 1 payment
|
| bluebird bio | Lyfgenia | $20 | 1 payment
|
| Incyte | Monjuvi | $16 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $15 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $15 | 1 payment
|
| Array Biopharma | Xalkori | $13 | 2 payments
|
2023: $3,811
| Sobi | Doptelet | $2,781 | 2 payments
|
| Pfizer | Oxbryta | $146 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $139 | 17 payments
|
| Novartis Pharmaceuticals | Promacta | $128 | 9 payments
|
| Astellas Pharma US | Xospata | $100 | 2 payments
|
| Seagen | None | $100 | 1 payment
|
| Daiichi Sankyo | Injectafer | $85 | 4 payments
|
| Exelixis | Cabometyx | $51 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Epkinly | $48 | 1 payment
|
| Lilly USA | Verzenio | $32 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $30 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $28 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $24 | 1 payment
|
| Amgen | Lumakras | $21 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $21 | 1 payment
|
| Celgene | Pomalyst | $20 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $19 | 1 payment
|
| Genentech USA | Tecentriq | $15 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $15 | 1 payment
|
| Emmaus Medical | Endari | $5 | 1 payment
|
2022: $12,348
| Genzyme | None | $6,959 | 6 payments
|
| Genentech | Venclexta | $4,841 | 4 payments
|
| Lilly USA | None | $108 | 1 payment
|
| Astellas Pharma US | None | $100 | 1 payment
|
| ADC Therapeutics America | None | $99 | 1 payment
|
| Amgen | None | $83 | 1 payment
|
| Genentech USA | Tecentriq | $33 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | None | $32 | 2 payments
|
| Pharmacosmos Therapeutics | Monoferric | $24 | 1 payment
|
| Pfizer | Xalkori | $19 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $17 | 1 payment
|
| Kite Pharma | None | $17 | 1 payment
|
| Daiichi Sankyo | Injectafer | $16 | 1 payment
|
2021: $1,617
| MorphoSys US | Monjuvi | $1,448 | 2 payments
|
| Genzyme | None | $125 | 1 payment
|
| GlaxoSmithKline | Blenrep | $29 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $15 | 1 payment
|
2020: $359
| Seagen | None | $99 | 1 payment
|
| Astellas Pharma US | Xospata | $91 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $59 | 4 payments
|
| Genzyme | Elitek | $24 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $17 | 1 payment
|
| Kite Pharma | Yescarta | $17 | 1 payment
|
| Sanofi-Aventis U.S. | Cablivi | $13 | 1 payment
|
2019: $3,469
| Seattle Genetics | Adcetris | $2,264 | 4 payments
|
| Astellas Pharma US | Xospata | $217 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $179 | 38 payments
|
| Puma Biotechnology | Nerlynx | $168 | 9 payments
|
| Janssen Biotech | Erleada | $121 | 10 payments
|
| Octapharma USA | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) | $63 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $51 | 3 payments
|
| Gilead Sciences | None | $45 | 3 payments
|
| Genentech USA | Gazyva | $39 | 2 payments
|
| TerSera Therapeutics | Varubi | $38 | 2 payments
|
| Amgen | Neulasta | $28 | 1 payment
|
| Genzyme | Elitek | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Jivi | $23 | 1 payment
|
| Eisai | Lenvima | $22 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| Pfizer | Xalkori | $18 | 1 payment
|
| Incyte | Jakafi | $17 | 1 payment
|
| Stemline Therapeutics | Elzonris | $17 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $16 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $16 | 1 payment
|
| Verastem | Copiktra | $16 | 1 payment
|
| Celgene | Pomalyst | $15 | 1 payment
|
| Emmaus Medical | Endari | $14 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $14 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $12 | 1 payment
|
| Tesaro | Zejula | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase 3 Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To Eltrombopag in Patients With Primary Immune Thrombocytopenia (Itp) Who Had An Insufficient Response Or Relapsed After First Line Steroid Treatment (Vayhit2) · 2024 | Their institution | $86,680 |
| Novartis Pharmaceuticals Corporation · A Phase III, Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To First-Line Corticosteroids in Primary Immune Thrombocytopenia (Vayhit1) · 2025 | Their institution | $52,884 |
| Novartis Pharmaceuticals Corporation · A Phase III, Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To First-Line Corticosteroids in Primary Immune Thrombocytopenia (Vayhit1) · 2024 | Their institution | $46,718 |
| ABBVIE INC. · A Study To Evaluate the Risk of Tumor Lysis Syndrome (Tls) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab Or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (Cll) · 2025 | Their institution | $35,651 |
| Stemline Therapeutics Inc. · Stml-401-0314 · 2022 | Their institution | $29,244 |
| ABBVIE INC. · Phase 2 Study of Venetoclax With Alternative Hma for Patients With Treatment Naive Unfit Aml With Prior Hma Failure · 2023 | Their institution | $14,248 |
| Novartis Pharmaceuticals Corporation · A Phase 3 Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To Eltrombopag in Patients With Primary Immune Thrombocytopenia (Itp) Who Had An Insufficient Response Or Relapsed After First Line Steroid Treatment (Vayhit2) · 2025 | Their institution | $13,475 |
| Novartis Pharmaceuticals Corporation · A Phase III, Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To First-Line Corticosteroids in Primary Immune Thrombocytopenia (Vayhit1) · 2023 | Their institution | $1,676 |
| Novartis Pharmaceuticals Corporation · A Phase 3 Randomized, Double-Blind Study of Ianalumab (Vay736) Versus Placebo in Addition To Eltrombopag in Patients With Primary Immune Thrombocytopenia (Itp) Who Had An Insufficient Response Or Relapsed After First Line Steroid Treatment (Vayhit2) · 2023 | Their institution | $1,236 |
Professional record
- NPI
- 1487802385
- Licence
- CA A150043California A150043: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Hospitalist (208M00000X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2008-09-04
- NPI last updated
- 2021-01-27
- NPI record certified
- 2021-01-27
This is when the NPI record was last certified, not a medical board exam.